Freeline Therapeutics Holdings PLC expected to post a loss of 97 cents a share - Earnings Preview

Freeline Therapeutics Holdings

13/08/2021 13:55

* Freeline Therapeutics Holdings PLC  FRLN.OQ   FRLN.O  is
expected to report results on August 16.
​* Refinitiv's mean analyst estimate for Freeline Therapeutics
Holdings PLC is for a loss of 97 cents per share. 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Freeline
Therapeutics Holdings PLC is $26​, about 84.7% above​ its last
closing price of $3.99. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.77       -0.78      -0.98     Missed  -25.2
 Dec. 31 2020              -0.70      -0.88     Missed  -24.8
 Sep. 30 2020              -0.72                        ​
 ​​            ​                                        ​
                                                        ​
 This summary was machine generated August 13 at 12:55 GMT.  All
figures in US dollars unless otherwise stated